Cantor Fitzgerald Forecasts RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings of $1.05 per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $23.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share.

A number of other equities analysts have also weighed in on RIGL. B. Riley boosted their price objective on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Rigel Pharmaceuticals in a research report on Wednesday, March 5th. Citigroup boosted their price objective on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Wall Street Zen downgraded Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 8th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.40.

Rigel Pharmaceuticals Stock Performance

NASDAQ RIGL opened at $21.56 on Tuesday. The stock’s fifty day moving average is $18.76 and its two-hundred day moving average is $19.85. The firm has a market capitalization of $385.32 million, a P/E ratio of 154.01 and a beta of 1.29. Rigel Pharmaceuticals has a fifty-two week low of $7.48 and a fifty-two week high of $29.82.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.49. The company had revenue of $53.33 million for the quarter, compared to analyst estimates of $43.87 million. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. During the same quarter in the previous year, the company posted ($0.50) earnings per share.

Hedge Funds Weigh In On Rigel Pharmaceuticals

Several hedge funds have recently bought and sold shares of RIGL. Armistice Capital LLC grew its holdings in Rigel Pharmaceuticals by 31.6% during the 1st quarter. Armistice Capital LLC now owns 1,516,000 shares of the biotechnology company’s stock valued at $27,273,000 after buying an additional 364,000 shares during the last quarter. Soleus Capital Management L.P. grew its holdings in Rigel Pharmaceuticals by 21.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,130,679 shares of the biotechnology company’s stock valued at $19,018,000 after buying an additional 195,891 shares during the last quarter. Vanguard Group Inc. grew its holdings in Rigel Pharmaceuticals by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 1,028,072 shares of the biotechnology company’s stock valued at $18,495,000 after buying an additional 15,141 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Rigel Pharmaceuticals by 50.1% during the 1st quarter. Acadian Asset Management LLC now owns 565,045 shares of the biotechnology company’s stock valued at $10,161,000 after buying an additional 188,679 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in Rigel Pharmaceuticals by 27.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 522,781 shares of the biotechnology company’s stock valued at $9,405,000 after buying an additional 112,003 shares during the last quarter. 66.23% of the stock is owned by hedge funds and other institutional investors.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.